PHM 431 Exam 1 Questions With Correct
Answers
An |inhibitory |of |the |enzyme |dopamine-β-hydroxylase |will |reduce |brain |levels |of |which |of |the |
following |neurotransmitters?
A) |dopamine
B) |norepinephrine
C) |serotonin
D) |acetylcholine |- |CORRECT |ANSWER✔✔-Norepinephrine
The |equilibrium |constant |for |a |drug |is |a |measure |of |drug |_______ |- |CORRECT |ANSWER✔✔-
Affinity
What |is |a |disadvantage |of |intravenous |drug |administration? |- |CORRECT |ANSWER✔✔-High |risk |
of |exceeding |the |toxic |drug |level
When |an |agonist |binds |to |its |receptor, |the |agonist |causes |a |response |in |the |target |cell |but |it |
also |causes |receptor |internalization. |This |is |a |mechanism |that |can |explain |__________ |- |
CORRECT |ANSWER✔✔-Receptor |downregulation
What |are |3 |factors |that |can |contribute |to |addiction |and |continued |drug |use? |- |CORRECT |
ANSWER✔✔-Drug |tolerance, |dependence, |and |withdrawal
GTP-γ-S |is |a |drug |that |irreversibly |activates |G-proteins. |One |effect |of |treating |neurons |with |
this |drug |would |be:
A) |increased |synthesis |of |norepinephrine
B) |increased |microtubule |trafficking |of |synaptic |vesicle |proteins
, C) |upregulation |of |receptors
D) |increased |levels |of |intracellular |cyclic |3',5' |AMP |- |CORRECT |ANSWER✔✔-Increased |levels |of
|intracellular |cyclic |3',5' |AMP
One |consequence |of |"knockout" |or |deletion |of |the |gene |that |encodes |the |enzyme |
phenylethanolamine-N-methyl-transferase |would |be:
A) |depletion |of |dopamine |stores |in |nerve |terminals |in |the |nucleus |accumbens
B) |depletion |of |norepinephrine |content |in |the |locus |ceruleus
C) |depletion |of |epinephrine |from |the |adrenal |medulla
D) |depletion |of |acetylcholine |from |the |nucleus |basalis |- |CORRECT |ANSWER✔✔-depletion |of |
epinephrine |from |the |adrenal |medulla
Drugs |which |inhibit |acetylcholinesterase |would |enhance |neurotransmission |in |which |of |the |
following |brain |regions?
A) |Septohippocampal |neurons
B) |Ventral |tegmental |area |neurons
C) |Dorsal |raphe |neurons
D) |Locus |ceruleus |neurons |- |CORRECT |ANSWER✔✔-Septohippocampal |neurons
Knockout |of |the |gene |that |encodes |the |enzyme |monoamine |oxidase |(MAO) |would |result |in |
enhanced |transmission |at |which |kind |of |synapse?
A) |5-HT |synapses
B) |dopamine |synapses
C) |norepinephrine |synapses
D) |all |of |the |above |- |CORRECT |ANSWER✔✔-5-HT |synapses, |dopamine |synapses, |and |
norepinephrine |synapses
The |EC50 |is |a |measure |of |drug |______ |- |CORRECT |ANSWER✔✔-Potency
Answers
An |inhibitory |of |the |enzyme |dopamine-β-hydroxylase |will |reduce |brain |levels |of |which |of |the |
following |neurotransmitters?
A) |dopamine
B) |norepinephrine
C) |serotonin
D) |acetylcholine |- |CORRECT |ANSWER✔✔-Norepinephrine
The |equilibrium |constant |for |a |drug |is |a |measure |of |drug |_______ |- |CORRECT |ANSWER✔✔-
Affinity
What |is |a |disadvantage |of |intravenous |drug |administration? |- |CORRECT |ANSWER✔✔-High |risk |
of |exceeding |the |toxic |drug |level
When |an |agonist |binds |to |its |receptor, |the |agonist |causes |a |response |in |the |target |cell |but |it |
also |causes |receptor |internalization. |This |is |a |mechanism |that |can |explain |__________ |- |
CORRECT |ANSWER✔✔-Receptor |downregulation
What |are |3 |factors |that |can |contribute |to |addiction |and |continued |drug |use? |- |CORRECT |
ANSWER✔✔-Drug |tolerance, |dependence, |and |withdrawal
GTP-γ-S |is |a |drug |that |irreversibly |activates |G-proteins. |One |effect |of |treating |neurons |with |
this |drug |would |be:
A) |increased |synthesis |of |norepinephrine
B) |increased |microtubule |trafficking |of |synaptic |vesicle |proteins
, C) |upregulation |of |receptors
D) |increased |levels |of |intracellular |cyclic |3',5' |AMP |- |CORRECT |ANSWER✔✔-Increased |levels |of
|intracellular |cyclic |3',5' |AMP
One |consequence |of |"knockout" |or |deletion |of |the |gene |that |encodes |the |enzyme |
phenylethanolamine-N-methyl-transferase |would |be:
A) |depletion |of |dopamine |stores |in |nerve |terminals |in |the |nucleus |accumbens
B) |depletion |of |norepinephrine |content |in |the |locus |ceruleus
C) |depletion |of |epinephrine |from |the |adrenal |medulla
D) |depletion |of |acetylcholine |from |the |nucleus |basalis |- |CORRECT |ANSWER✔✔-depletion |of |
epinephrine |from |the |adrenal |medulla
Drugs |which |inhibit |acetylcholinesterase |would |enhance |neurotransmission |in |which |of |the |
following |brain |regions?
A) |Septohippocampal |neurons
B) |Ventral |tegmental |area |neurons
C) |Dorsal |raphe |neurons
D) |Locus |ceruleus |neurons |- |CORRECT |ANSWER✔✔-Septohippocampal |neurons
Knockout |of |the |gene |that |encodes |the |enzyme |monoamine |oxidase |(MAO) |would |result |in |
enhanced |transmission |at |which |kind |of |synapse?
A) |5-HT |synapses
B) |dopamine |synapses
C) |norepinephrine |synapses
D) |all |of |the |above |- |CORRECT |ANSWER✔✔-5-HT |synapses, |dopamine |synapses, |and |
norepinephrine |synapses
The |EC50 |is |a |measure |of |drug |______ |- |CORRECT |ANSWER✔✔-Potency
